CLEOPATRA Study in Metastatic HER2+ Breast Cancer

  • The CLEOPATRA study:
    • Showed that the combination of docetaxel, trastuzumab, and pertuzumab:
      • Led to improved progression free survival (PFS) compared to docetaxel, trastuzumab, and placebo:
        • 18.5 months vs. 12.4 months
  • Surgery for the primary site is not indicated for patients with distant metastatic disease in the absence of symptoms

References

1. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New Engl J Med.2012;366(2):109-119.

2. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s